HIV Treatment Bulletin - Vol. 5, No. 6, July 2004
Simon Collins, HIV I-Base

Earlier studies were have investigated the use of IL-7 to stimulate latently infected CD4 cells to express HIV and therefore render them susceptible to effect of antiretroviral treatment. If this response was sufficiently extensive and robust, this would re-open discussions on possibilities of HIV eradication.

An abstract at the meeting reported further ex-vivo research in cell cultures with IL-7 and two previously unreported drugs: valproic acid (VPA), an inhibitor of histone deacetylase (HDAC), a host mediator of gene expression; and an investigational p38 kinase inhibitor that should similarly inhibit HDAC. All three drugs induced outgrowth in cells from 4/4, 5/5 and 2/2, patients ‘at concentrations achievable in vivo’ of IL-7, VPA and the p38 KI respectively, without inducing cell activation.

Comment

This preliminary work is complementary to research using other approaches aimed at draining the latent reservoir, such as prostatin. Novel agents which can either selectively kill HIV infected cells (virucidal agents) or induce expression of virus in the latent reservoir so that the currently licensed virustatic antiretroviral drugs can clear that remaining virus are the most promising leads we currently have towards viral eradication.

However a serious problem with viral induction is that promotion of global T-cell activation leads to highly problematic inflammatory consequences.

Such approaches have been investigated before, for example using combined IL-2 and anti-CD3 monoclonal antibody therapy, and were extremely toxic (ref: Kulkosky J et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 2001 Nov 15;98(10):3006-15.

The new strategy described here, which does not involve cellular activation, is unlikely to be dogged by the same problems.

Ref: Margolis DM, Lehrman G, Archin NM et al. Targetting reservoirs of HIV infection: inducing latent viral expression without host cell activation. Antiviral Therapy 2004; 9:S77 (abstract 68).

040710
IB040506-08

©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.